Le Lézard
Classified in: Health
Subject: HEALTH

Marijuana Victims' Association: Is Marijuana the New Thalidomide


VANCOUVER, BRITISH COLUMBIA--(Marketwired - Aug. 4, 2016) - Phocomelia (limb malformation) has been shown in testing(i) of THC marijuana in a similar preclinical model to that which revealed the teratogenicity of thalidomide.

The federal government is aware of serious marijuana harms; it must not be complicit in risking Canadian health, but must mitigate by placing marijuana products under a protective protocol similar to REVAID used for Thalidomide.

As the stewards of the country's human and financial resources, it is critical that government protect the public from potential irreversible harm and itself from litigation. Marijuana harm is not only possible but probable.

A Health Canada document cites 1,000 scientific references that substantiate the risks.

The June 2016 Government public consultation discussion paper fails to inform the public of the risks, specifically to the fetus and reproduction by males.

If thalidomide offered the "high" of pot would it be reasonable to legalizing it for recreational use?

(i)Ref: Reece AS, Hulse GK. Chromothripsis and epigenomics complete causality criteria for cannabis- and addiction-connected carcinogenicity, congenital toxicity and heritable genotoxicity. Mutat Res. 2016;789:15-25.

Contact Information:
Marijuana Victims' Association
Pamela McColl
SAM Canada
1-778 354 3551

These press releases may also interest you

at 03:05
CULT Food Science Corp. ("CULT" or the "Company") (FRA: LN00), a disruptive food technology platform pioneering the commercialization of lab grown meat and cellular agriculture to reshape the global food industry, congratulates venture arm company,...

at 03:00
Novo Holdings, a leading life science investor, today announces it led a...

at 03:00
Financing led by Novo Holdings, including new investment from EQT Life Sciences ? LSP Dementia Fund, OrbiMed and SR One with participation from existing investors M Ventures, Sofinnova Partners, GSK Equities Investments Limited and Johnson & Johnson...

at 02:05
Catalent, Inc. , the leader in enabling the development and supply of better treatments for patients worldwide, today announced it has completed expansion of its clinical supply facility in Schorndorf, Germany. The Schorndorf site, Catalent's...

at 01:05
SamanTree Medical, a leading medical technology company specializing in innovative solutions to improve the outcomes of surgery, today announced the closing of $14M as part of a Series B financing round. The new capital will be used to further...

at 01:00
CordenPharma is making a record investment of ~?900m over the next 3 years in expanding its peptide platform, both at its Colorado, US site and in Europe. The expansions, covering both existing facilities and new constructions, will meet the...



News published on and distributed by: